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Correction to: Cholestyramine treatment in
two dogs with presumptive bile acid
diarrhoea: a case report
L. Toresson1,2*, J. M. Steiner3 and J. S. Suchodolski3
Correction to: Canine Med Genet 8, 1 (2021)
https://doi.org/10.1186/s40575-021-00099-x
Following publication of the original article [1], the au-
thors identified an error that mg/kg should be g/kg in
the Discussion section.
The correct sentences should read:
One recent study reported that a cholestyramine dose
of 0.7 g/kg q 24 h administered for 14 days to 12 healthy
Beagle dogs appeared to be clinically safe [32]. No side
effects or weight loss were noted. The faecal dry matter
content increased with cholestyramine treatment, but
the number of bowel movements did not increase and
faecal scores were still in the normal range. Macro- nu-
trient apparent total tract digestibility decreased after
cholestyramine treatment, but remained in the normal
range. It should be noted that the dose used in these
studies was 7 times higher than the doses used in this
case report (0.058 g/kg q 12 h and 0.059 g/kg q 12 h,
respectively).
The original article [1] has been corrected.
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